

COMPLETE IF KNOWN

(use as many sheets as necessary)



Application Number	10/560,290
Filing Date	December 12, 2005
First Named Inventor	H. Sings et al.
Group Art Unit	--
Examiner Name	--
Attorney Docket Number	21278P


[illegible][illegible]

Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/560,290	
			Filing Date	December 12, 2005	
			First Named Inventor	H. Sings et al.	
			Group Art Unit	--	
			Examiner Name	--	
Sheet	2	of	3	Attorney Docket Number	21278P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Kopelman, Nature, Vol. 404 (2000), pp. 635-643, "Obesity as a medical problem"
	AB	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"
	AC	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selected antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats"
	AD	Chen et al., Cell, Vol. 91 (1997), pp. 789-798, "Exocrine gland dysfunction in MC5-R-deficient mice ..."
	AE	Giraud et al., Brain Res., Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"
	AF	Hill et al. Science, Vol. 280 (1998), pp. 1371-1374, "Environmental contributions to the obesity epidemic"
	AG	Corcos et al., Society for Neuroscience Abstracts, Vol. 23 (1997), Abstract No. 267.9, p. 673, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"
	AH	Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, June 14-19, 1997, Nashville, TN
	AI	Wessels et al., J. of Urology, Vol. 160 (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction ..."
	AJ	Dorr et al., Life Sciences, Vol. 58, No. 20 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"
	AK	Wessells et al., Urology, Vol. 56 (2000), pp. 641-646, "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction"
	AL	Graul, Drugs News & Perspectives, Vol. 9 (1996), pp. 572-575, "Latest findings on the diagnosis and treatment of erectile dysfunction"
	AM	Dinsmore et al., Brit. Med. J., Vol. 318 (1999), pp. 387-390, "ABC of sexual health -- erectile dysfunction"
	AN	Gingell et al., Exp. Opin. Ther. Patents, Vol. 9 (1999), pp. 1689-1696, "Emerging pharmacological therapies for erectile dysfunction"
	AO	Yoram et al., Current Opinion in Urology, Vol. 7 (1997), pp. 349-353, "Oral pharmacotherapy in erectile dysfunction"

Examiner Signature		Date Considered	10/1/07
--------------------	---	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/560,290
---------------------------	-------------------

Filing Date	December 12, 2005
--------------------	-------------------

First Named Inventor	H. Sings et al.
-----------------------------	------------------------

Group Art Unit	--
----------------	----

Examiner Name	--
---------------	----

Attorney Docket Number 21278P

NON PATENT LITERATURE DOCUMENTS

**Examiner
Initials***

**Cite
No.**

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

AP

Heaton et al., *Int'l J. of Impotence Res.*, Vol. 9 (1997), pp. 115-121, "A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative"

AQ

Budhu et al., Database Caplus on STN No. 130:223167 (1999), "Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity"

AR

Goulet et al., Database Caplus on STN No. 137:216872 (2002), "Acylated piperidine derivatives, specifically 1-[(aminocycloalkyl)carbonyl]piperidines, as melanocortin-4 receptor agonists, and their pharmaceutical ..."

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Copied from 10343019 on 10/16/2007